NCT06856954
The Skin Barrier in Users of Diabetes Devices
Recruiting · Not specified · Jannet Svensson · registry updated 2025-09-09
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Diabetes technology (insulin pumps and continuous glucose monitoring) have become standard of care in children with type 1 diabetes. Unfortunately, the attachment of the devices to the skin can provoke injury, irritative or allergic eczema of the skin. Additionally, the continuous insulin infusion often causes sub-cutaneous lipohypertrophy. These occurrences are likely to increase blood glucose fluctuation and impact burden of diabetes. In collaboration with dermatologists, the propose is to investigate the skin microcirculation and skin barrier as well as the subcutaneous tissue when exposed to insulin, occlusion, irritative and allergenic features of the part of device in close contact with the skin. Secondly, investigate the skin barrier and recovery time as a function of time since exposure, type of patches/device and use of preventive strategies like steroids, liquid barrier crème or local anesthetic. To study microcirculation the investgators use Tissue Viability Imaging (TiVI) a non-invasive method using polarization light spectroscopy to count red blood cells thereby saying something about the microcirculation....
Inclusion
- diagnosed with type 1 diabetes
- using diabetes device attached to the skin (insulin pump or CGM)
Exclusion
- Do not use diabetes device attached to the skin.
- Those unable to read and understand Swedish or English
- impaired cognitive development that may interfere with the ability to answer questionnaires in Swedish/English and/or be reached by phone.